Downloadable resources are posted below
1) Amgen 2016 Trends in Biosimilars Report. Co-written by Elan Rubinstein and Edelman Public Relations.. April 8, 2016. Available at: http://www.amgenbiotech.com/resources/2016_Amgen_Trends_in_Biosimilars_Report_USA-BIO-122466.pdf
2) CMS-1670-P: Grim gross margins of 1.8%-3.7% at proposed reimbursement and after sequester for cancer chemotherapy regimens + supportive care drugs. Reimbursement analysis by Elan Rubinstein. March 19, 2016
| elan_rubinstein_-_cms-1670-p_linkedin_blog_post_031916.pdf |
| e_rubinstein_-_cms-1670-p_-_pricing_analysis_of_2014_opps_mpfs_medicare_part_b_claims_data_-_031916.pdf |
3) Trends in Biosimilars Report - 2015. Amgen. Elan Rubinstein, research & editorial support. April 2015. Available at the following URL: http://www.amgenbiotech.com/resources/2015_Trends_in_Biosimilars_Report-83531R1V1.pdf.
4) Drug cost & innovation: Balancing societal needs & marketplace demands. Panel presentation. Elan Rubinstein. UCLA Health Forum. April 29, 2015.
| ucla_health_forum_-_e_rubinstein_-_drug_prices_&_innovation_-_042515.pdf |
5) Site of care optimization for specialty pharmaceuticals. Elan Rubinstein. CBI Specialty Therapies - Forum for Payers. January 30, 2015
| cbi_specialty_therapies_-_soc_optimization_-_final_010715.pdf |
6) US specialty pharmaceuticals marketplace with hepatitis C case study. Elan Rubinstein. Seminar in healthcare decision analysis. USC School of Pharmacy & USC Schaeffer Center for Health Policy & Outcomes. July 13, 2014
| specialty_pharmacy_-_e_rubinstein_slide_deck_-_usc_health_policy_july_13_-_061914.pdf |
7) Prescription pharmaceuticals in 2014: What's ahead for payers? Elan Rubinstein. Health Forum at UCLA. UCLA School of Public Health. February 26, 2014
| ucla_health_policy_-_february_26_2014_-_e_rubinstein_022114.pdf |
8) Evaluation of increased adherence and cost savings of an employer value-based benefits program targeting generic antihyperlipidemic and antidiabetic medications. B Clark, J DuChane, J Hou, E Rubinstein, J McMurray, I Duncan. Journal of Managed Care Pharmacy. February 2014
| jmcp_-_b_clark_-_evaluation_of_increased_adherence__cost_savings_of_employer_value-based_benefits_program_targeting_generic_medications_0214.pdf |
9) What may self-insured employers do to impact specialty pharmaceuticals benefit, cost and trend? Elan Rubinstein. CBI Specialty Therapies - A Forum for Payers. Las Vegas, NV. January 31, 2014
| cbi_specialty_rx_-_elan_rubinstein_-_employer_perspective_-_final_013114.pdf |
10) AMCP Guide to Pharmaceutical Payment Methods, V3.0, 2013 Update. E Rubinstein, H Tag. Academy of Managed Care Pharmacy. May 2013. The Guide is available at the following URL: http://www.rbshelp.com/articles/AMCP-Pharmaceutical-Guide-Final.pdf
11) Oral chemotherapy program improves adherence and reduces medication wastage and hospital admission. N Khandelwal, I Duncan, T Ahmed, E Rubinstein, C Pegus. Journal of the National Comprehensive Cancer Network. May 2012
| jnccn_-_kandelwal_-_oral_chemotherapy_program_0312.pdf |
12) Community pharmacy and mail order costs and utilization for 90-day maintenance medication prescriptions. N Khandelwal, I Duncan, E Rubinstein, T Ahmed, C Pegus. Journal of Managed Care Pharmacy. April 2012
| jmcp_-_n_khandelwal_-_community_pharmacy_and_mail_order_cost_and_utilization_for_90-day_maintenance_medication_prescriptions_0412.pdf |
13) Overview of the specialty pharmacy marketplace, oncology in particular, and the role of group purchasing. Prepared for a day-long advisory group meeting of a large Group Purchasing Organization. October 2010
| specialty_pharmacy_landscape_-_elan_rubinstein_-_oct_2010.pdf |
